For people who survive a stroke, the most dangerous period often comes right after they leave the hospital, when the odds of a second, sometimes worse stroke are at their highest. Doctors have long tried to lower that risk with blood thinners, but stronger drugs have come with a familiar price: more serious bleeding.
Read next on Morning Overview: The Justice Department asked courts to undo approvals for three offshore wind farms, one already making power
A new pill takes a different route. Bayer’s asundexian, sold as Sunharbo, cut recurrent ischemic strokes by 26% in a large trial when added to standard antiplatelet drugs, without a significant overall increase in major bleeding. On November 9, the Food and Drug Administration approved it, making it the first drug of its kind on the U.S. market.
A 26% cut in repeat strokes in OCEANIC-STROKE
The approval rests on OCEANIC-STROKE, a phase 3, randomized, double-blind, placebo-controlled trial that enrolled 12,327 patients worldwide between January 2023 and February 2025, AJMC reported. Participants, with a mean age of 68, had a recent mild-to-moderate ischemic stroke or a high-risk transient ischemic attack, often called a mini-stroke. They were randomized within 72 hours of their symptoms to 50 milligrams of asundexian once a day or a placebo, on top of the antiplatelet therapy they would normally receive. More than half were planned to receive two antiplatelet drugs. Follow-up ranged from at least three months to as long as 31 months, and the trial is registered as NCT05686070. Ischemic stroke was the qualifying event for 95% of participants, and 27% of those strokes had been treated with clot-dissolving drugs or mechanical clot removal.
Over a median treatment period of about 14 months, 6.2% of patients taking asundexian had another ischemic stroke, compared with 8.4% of those taking placebo, according to HCPLive’s summary of the data. That works out to a 26% relative reduction and an absolute reduction of 2.2 percentage points. The benefit was consistent across subgroups, including different stroke subtypes, and secondary measures combining stroke, heart attack and cardiovascular death also favored the drug.
“For those who survive a stroke, the risk of another potentially devastating event is highest in the days and weeks after the initial event, and that risk persists over time,” said Dr. Ashkan Shoamanesh, co-principal investigator of the trial and a senior scientist at the Population Health Research Institute at McMaster University and Hamilton Health Sciences in Ontario. He called the drug an important new addition to post-stroke care.
Why factor XIa is a different target
Asundexian blocks activated factor XI, or factor XIa, one of the proteins in the cascade that forms blood clots. According to HCPLive, factor XIa plays a large role in the growth of dangerous clots inside blood vessels but a smaller role in forming the plug that seals a wound. Blocking it, in theory, slows harmful clots while leaving more of the body’s ability to stop bleeding intact.
The trial results matched that theory overall. Major bleeding, measured by International Society on Thrombosis and Haemostasis criteria, occurred in 1.9% of patients on asundexian and 1.7% on placebo, a difference that was not statistically significant, HCPLive reported. WebMD’s drug summary put the annual rates at 1.6% and 1.5%.
The overall numbers hide important exceptions, and the FDA label reflects them. Major bleeding was more common in patients older than 75 and during the first 90 days of treatment, and gastrointestinal bleeding was more frequent with asundexian. The label also warns about use with drugs that strongly induce the liver enzyme CYP3A4 or the P-gp transporter, and in patients with liver impairment. Diarrhea was the most common side effect. The early benefit was also less clear: strokes within the first 90 days were not significantly different between groups, at 3.0% versus 3.5%.
Who the drug is for, and who it is not
The approval is narrow. Sunharbo is approved, in combination with antiplatelet therapy, for adults after a recent mild-to-moderate noncardioembolic ischemic stroke, one scored 15 or lower on the National Institutes of Health Stroke Scale, or a high-risk TIA. It is not approved for preventing strokes caused by atrial fibrillation, in which clots form in the heart, according to TCTMD. Patients in the trial were also required to have signs of atherosclerosis or a nonlacunar infarct, which describes a common group of stroke patients but not all of them.
Asundexian received fast track and priority review designations before its approval. Its arrival makes it the first of a new class of anticoagulants to reach patients, a class that drugmakers have pursued for years in hopes of separating clot prevention from bleeding risk. For the many stroke survivors who already take one or two antiplatelet pills, the decision about adding a third drug will rest with their doctors, weighing the 26% reduction in repeat strokes against age, bleeding history and the higher bleeding risk the label flags early in treatment.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Zero Motorcycles unveiled an electric motorcycle targeted at under $8K and a street-legal dirt bike at EICMA
- New FCC rules on how people can stop robocalls and texts take effect Nov. 25
- Neanderthals in Spain carved a wooden object that matches nothing archaeologists have ever found
- The FAA wants $2.39 million from a flight school it says flew a Cessna about 280 times with an unapproved part